Approved and currently in-use ICI for skin cancer treatment include cytokines that target the IL-2 and IFNAR1/2 pathways such as aldesleukin and interferon/peginterferon alfa-2b, PD-1 inhibitors such as pembrolizumab and nivolumab, PD-L1 inhibitors such as atezolizumab, and the first clinically approved monoclonal antibody for CM, ipilimumab, that targets CTLA-4 [22]. This evidence concerns the gene IL2 and skin cancer.